跳到正文
GEN 新闻· Alex Philippidis·· 14 小时前精选AI 评分70

黄仁勋辞任英伟达 CEO,生命科学合作前景添变数

StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?

AI 导读

英伟达 CEO 黄仁勋因媒体报道的婚外情辞职,董事会任命自 2013 年起担任 CFO 的 Colette Kress 为临时 CEO,公司股价一周内下跌 12.75%,较 10 月 6 日 239.24 美元的收盘高点已回落 32%。

推荐理由

文中汇总了英伟达在生命科学领域的多项合作,并记录了分析师与合作伙伴就黄仁勋辞职后合作走向的公开表态。

正文 · 原文

Shakespeare and Greek mythology have met their match with the dramatic personal downfall story that culminated in Jensen Huang’s sudden resignation as CEO of Nvidia (Nasdaq: NVDA) amid turmoil caused by up to three reported extramarital affairs. While Nvidia doesn’t develop new therapies, instruments, or reagents, its AI technology powers numerous collaborations with biopharma and lab tools giants stretching back at least five years.

Nvidia’s board named Colette Kress as interim CEO. Kress has served as executive vice president and CFO since joining the company in 2013.

“The Board has full confidence in Colette and the leadership team, and we expect the company’s operations, customer commitments, and product roadmap to continue without interruption,” Harvey C. Jones, an Nvidia board member since 1993 who was named chair on Thursday, said in a statement. Jones is an entrepreneur, technology executive, and active venture investor who had served as CEO and executive chairman of silicon design provider Synopsys.

The first reported affair raised national security issues after Huang disclosed in a letter to Nvidia employees made public November 8 that he had conducted an extramarital relationship with Alice Huang (no relation), founder of Megaspeed International, an Nvidia customer and Singapore-based provider of cloud computing and AI infrastructure services. The disclosure touched off an investigation by Nvidia’s board into Jensen Huang’s relationship with Alice Huang, who according to U.S. intelligence officials may have passed along sensitive information to China’s Ministry of State Security; Beijing has denied she carried out any intelligence activity for China.

Three days later on Wednesday, The New York Times cited five unnamed sources in reporting that Huang had an extramarital relationship with an Nvidia executive identified by the newspaper as Kimberly Powell, who as vice president of healthcare and life sciences served as Nvidia’s top executive overseeing its hardware and software platforms for accelerated computing, AI, and visualization in applications ranging from drug discovery to medical imaging and healthcare analytics. The following day, Reuters cited two unnamed sources in reporting an affair between Jensen Huang and a second Nvidia employee whom it did not name.

“OK, this is very, very, very sad, and may and will have dramatic consequences for the entire industry,” Alex Zhavoronkov, PhD, the founder, CEO, and CBO of Insilico Medicine (Hong Kong Exchange: 3696),” posted Thursday on X. “Now, half of the massively overvalued AI drug discovery startups with no productivity metrics, no drugs, and no long-term moat will not be able to fundraise from Nvidia for a while.”

Bedroom bubble burst

“Who knew that the AI bubble would burst in the employee bedroom…,” added Zhavoronkov, who also leads Insilico’s board as chairman and executive director. He added in a separate post: “Let’s hope it all settles without too much drama and Jensen keeps working hard (and probably even harder).”

On Friday, Zhavoronkov recalled how during his company’s struggling early years, Jensen Huang recorded a video marking the launch of Insilico’s Pharma.AI drug discovery platform: “When Jensen recorded this video in 2022 2 weeks before the launch of consumer ChatGPT, I honestly could not hold my tears. When I watched it today, I could not hold my tears either.”

“Some of my followers on LinkedIn are even celebrating. There is nothing to celebrate. This is a real tragedy and it will have industry-scale consequences. I truly hope that Jensen comes back in some capacity,” Zhavoronkov added. “To all my friends at NVIDIA—please stay strong and let’s work together to solve aging. Support Jensen and his wonderful family. We respect you and love you even though we [are] not a buyer of chips.”

The reported affairs and resignation of Huang sent Nvidia shares sinking this past week. The declines compounded a month-long Nvidia stock slide stemming from investor worries about whether the spending of tech giants on AI infrastructure will result in sustainable cash flow, profits, and revenue quickly enough to justify the expense. Those fears have caused Nvidia stock to nosedive 32% since hitting a record closing price of $239.24 on October 6.

Nvidia shares began the week slipping 4% on November 9, from $186.64 to $178.67.  Shares slid another 5.5% Tuesday to $168.89, rebounded nearly 3% Wednesday to $173.73, then fell again 4% Thursday to $166.19 after starting that day tumbling 14% following Huang’s resignation. Shares finished this past week dipping 2% Friday, closing at $162.85—a five-day decline of 12.75%.

“The stakes behind Huang’s resignation reveal the murky waters that businesses using AI are swimming in,” Asa Hiken, senior analyst with Emarketer, wrote in a commentary posted on the website of the market research and digital intelligence company. “On the surface, AI is a tool for powering productivity, creative production, or novel customer experiences, but in the depths it’s a swelling geopolitical powder keg. Disentangling these two sides of the technology is impossible.”

Stacy Rasgon, managing director and senior analyst, U.S. semiconductors and semiconductor capital equipment at Bernstein Research, cautioned that Nvidia’s challenges have not ended with the resignation of Jensen Huang.

“Considerable uncertainty”

“We see considerable uncertainty around further news flow that is probably going to be coming down the pipe, as well as the ability of any new CEO to truly fill Jensen’s shoes given how tightly he managed the direction of the business and its relationships with customers, suppliers, employees, and the broader industry ecosystem,” Rasgon wrote in a research note, as reported by Bloomberg News.

Nvidia and its venture arm NVentures participated in 122 startup funding deals in 2026 as of Friday, according to Crunchbase, while PitchBook counted 67 such deals in 2025 and 54 in 2024. Given Nvidia’s investment in AI startups, Rasgon wrote: “We wonder what will happen to the company’s myriad of investments in the space, various backstops and residual guarantees.” Rasgon downgraded Bernstein’s rating on Nvidia stock to “Market Perform” and lowered the firm’s price target to $200.

“Our gut tells us that we probably haven’t yet fully probed the depths of what might be found here,” Rasgon commented, adding: “We’ve had enough, and prefer to watch from the sidelines.”

A recent example of Nvidia’s life sciences footprint came earlier this month when 10x Genomics (Nasdaq: TXG), a developer of scalable single-cell and spatial biology platforms, launched Sentira Single Cell, a cloud-based agentic analysis application for users of the company’s Chromium single-cell platform, powered by the Claude models of Anthropic (Nasdaq: ANT; IPO pending). The launch came weeks after 10x unveiled Sentira Spatial Analysis for users of 10x’s Atera in situ spatial biology and transcriptomics platform.

Both applications apply Nvidia’s accelerated computing capabilities with the aim of speeding up widely used biological analysis methods; Sentira Spatial Analysis, for example, can reduce the analysis iteration cycle from hours on CPU alternatives to minutes. Underpinning that speed is rapids-singlecell, an open-source, GPU-accelerated Python library designed for large-scale single-cell omics analysis such as single-cell RNA sequencing. Rapids-singlecell was co-developed by Nvidia with scverse, an open-source, community-governed ecosystem of packages for single-cell and spatial omics.

“Incredibly powerful company”

“Nvidia is an incredibly powerful company, and it’s not just one person who made it so,” Serge Saxonov, PhD, 10x’s co-founder and CEO, told GEN when asked whether recent Nvidia news including Huang’s resignation would cause 10x to review the partnership. “We’ve had an incredible relationship with the people over there. They’ve done incredible work in this collaboration.”

Over the past five years, Nvidia has initiated a variety of partnerships with tools developers, drug developers, and others within the life sciences. During the J.P. Morgan Healthcare Conference in January, Nvidia launched a pair of collaborations with life-sci giants: The company joined Eli Lilly (NYSE: LLY) in committing $1 billion over five years to create a “Co-Innovation AI Lab” designed to address key challenges in AI drug discovery. Nvidia also announced plans to integrate its AI technology into the lab instruments of Thermo Fisher Scientific (NYSE: TMO) through a collaboration intended to develop intelligent and increasingly autonomous laboratories.

Through a spokesperson, Thermo Fisher confirmed receipt of GEN’s query but offered no comment.

Also on the tools side, Danaher (NYSE: DHR) agreed to partner with Nvidia last month. Danaher agreed to combine its scientific instrumentation, automation technologies, laboratory workflow software, and domain expertise with Nvidia’s accelerated computing and AI technologies.

Nvidia in recent years has also partnered with the Novo Nordisk Foundation, the nonprofit majority owner of Lilly’s arch-rival in obesity and diabetes drug development Novo Nordisk (Nasdaq Copenhagen: NOVO-B; NYSE: NVO).  The foundation agreed in June 2025 to house an Nvidia supercomputer at the Danish Centre for AI Innovation, which last month announced it had invested in 32 NVIDIA DGX Rubin NVL8 systems, giving Denmark access to the latest generation of AI infrastructure.

Earlier, Nvidia partnered with British-based pharma giants AstraZeneca (London, Nasdaq Stockholm, and NYSE: AZN) and GlaxoSmithKline (London: GSK) to build the U.K.’s most powerful supercomputer, Cambridge-1, in 2020 through a partnership that also included the kingdom’s National Health Service (NHS).

Spokespeople for Lilly, AstraZeneca, and GSK at deadline had not responded to GEN queries about whether they would review their partnerships with Nvidia. Novo Nordisk referred GEN to the Danish Centre for AI Innovation, which at deadline had not responded either.

“Nvidia’s strength has always come from its people, and together with our leadership team, I am committed to building on the extraordinary foundation Jensen created over the last 33 years,” Kress said in a statement. “We will continue advancing the work that has made Nvidia a leader in accelerated computing and AI, and execute on the opportunities ahead. Our focus remains on serving our customers, partners, developers and shareholders.”

PepGen nearly doubles on record-setting data

PepGen (Nasdaq: PEPG) nearly doubled its stock price this past week after announcing dazzling mid-stage clinical results for its lead pipeline candidate PGN-EDODM1 that included the highest level of splicing correction ever reported in a multiple dose trial in patients with myotonic dystrophy type 1 (DM1).

PepGen shares rocketed 82% from $2.39 on Tuesday, when it announced its record-setting data, to $4.36 at Friday’s closing bell. The stock surge began when PGN-EDODM1, an enhanced delivery oligonucleotide (EDO) designed to address the underlying molecular mechanism of DM1, aced the Phase II FREEDOM2-DM1 trial (NCT06667453). PGN-EDODM1 attained a record-breaking 46.5% mean splicing correction in muscle, with four of six participants showing more than 50% splicing correction and all but one of the six, more than 20% splicing correction as measured by the 22-gene panel at Week 13.

In contrast, a pooled group of four participants receiving placebo (combined from Cohorts 1 and 2) showed a mean splicing correction of just 6.8% was 6.8% at Week 13.

Participants also showed sustained improvements in the video Hand Opening Time (vHOT), hand grip strength, 10-Meter Walk/Run Test (10MWRT), and Timed Up and Go (TUG) functional assessments—data that PepGen said offered compelling evidence of PGN-EDODM1’s potential to address multiple clinical manifestations of DM1 and supporting continued development.

“Our ambition is to fundamentally change how DM1 is treated through greater targeting of the underlying molecular mechanism of the disease,” James McArthur, PhD, PepGen’s president and CEO, said in a statement. “The 10 mg/kg results mark an important milestone in that pursuit, with robust splicing correction accompanied by encouraging improvements across multiple measures of muscle function.”

McArthur said the data strengthened PepGen’s confidence not only in PGN-EDODM1’s potential, but in the company’s broader development strategy.

“With our 12.5 mg/kg cohort fully enrolled and the ongoing FREEDOM-OLE study exceeding 135 doses administered, we believe we are well positioned to continue building the evidence needed to advance toward pivotal studies,” the CEO added.

PepGen quickly sought to cash in on its clinical triumph by launching a $125 million public offering of its common stock—though some investors could instead opt for pre-funded warrants to purchase shares of the stock. Net proceeds from the offering are intended, PepGen said, to fund ongoing clinical development of PGN-EDODM1, as well as provide working capital and address other general corporate purposes.

PepGen also granted the underwriters of its offering a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. Leerink Partners, Stifel, and Guggenheim Securities acted as joint bookrunning managers for the proposed offering.

“New bar in DM1”

PepGen’s clinical success quickly won over analysts and investors.

“PEPG’s best-in-disease splicing and vHOT with favorable (renal) safety at 10[mg/kg] sets the new bar in DM1,” declared Kostas Biliouris, PhD, a managing director on the biotechnology research team of Oppenheimer.

Similarly, Debjit Chattopadhyay, PhD, a senior managing director and equity research analyst covering the biotechnology sector at Guggenheim Securities—one of the joint bookrunning managers for the $125 million public offering—hailed PepGen’s results as “potentially the new benchmark for splicing,” according to several published reports. Chattopadhyay contrasted PepGen’s 49% mean correction with the 25% mean correction at three months reported last year by Dyne Therapeutics (Nasdaq:DYN) from its Phase I/II ACHIEVE trial (NCT05481879) evaluating a 6.8 mg/kg every eight weeks dose of DM1 candidate DYNE-101.

Tazeen Ahmad, a senior research analyst covering large-cap and small-cap biotechnology companies with BofA Securities, upgraded PepGen shares from “Underperform” to “Neutral,” and raised her firm’s 12-month price target on the company’s shares 140%, from $2.50 to $6.

Investors responded with a buying surge that sent PepGen stock nearly doubling on November 10, rocketing nearly 93% from $2.39 to $4.61. Shares soared another 14% Wednesday, reaching $5.26 before dropping 4% to $5.04 Thursday and skidding another 13.5% Friday.

Leaders and laggards

  • Capricor Therapeutics (Nasdaq: CAPR) shares jumped 26.5% from $8.87 to $11.22 Wednesday after JonesTrading upgraded its rating of the company’s stock from “Hold” to “Buy” with a $25 price target. JonesTrading cited the upcoming Prescription Drug User Fee Act (PDUFA) target action date of November 22 on the company’s re-submitted Biologics License Application (BLA) for its lead cell therapy candidate deramiocel in Duchenne muscular dystrophy (DMD). In August, Capricor proposed narrowing its indication to treating upper limb impairment in DMD patients >9 years old, the population studied in its HOPE-3 trial (NCT05126758) and the focus of its primary endpoint. The company also submitted two-year open-label extension data and additional robustness analyses from HOPE-3, and an integrated summary of efficacy across HOPE-3 and the earlier Phase II HOPE-2 trial (NCT03406780). The FDA classified the August submission as a major amendment, extending the review by three months from the original August 22 date.
  • Oragenics (NYSE American: OGEN) shares plummeted nearly 43% from 35 cents to 20 cents Friday, after the developer of intranasal brain-targeted therapeutics announced third quarter results showing a net quarterly loss of $2.603 million, and a nine-month net loss of $7.333 million. The stock plunge occurred despite positive news: The NYSE Regulation rules enforcement arm had accepted its plan to regain compliance with NYSE American listing standards and granted an extension through February 25, 2028 to do so. “We believe this approval allows us to maintain our NYSE American listing while we continue to pursue our strategic priorities, capital raising initiatives, and investment strategies designed to enhance long-term value for our shareholders,” CEO Janet Huffman stated. Oragenics lost compliance due to a low stockholders’ equity of $3.7 million as of June 30, plus losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2025.

The post StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations? appeared first on GEN - Genetic Engineering and Biotechnology News.

来源:GEN 新闻 · genengnews.com